The Thursday news reports: March 26, 2009

This morning’s news report addresses items on:

  • p53 overexpression and prostate cancer outcomes
  • Diet and prostate cancer in newly diagnosed patients and prostate cancer survivors
  • Outcomes of surgical treatment of men with clinical T1a and T1b disease
  • Peripheral androgen ablation in men with biochemical recurrence after first-line treatment … READ MORE …

Prostate cancer news review: Thursday, July 24

Newly published studies today include data on:

  • Risk for patients with prostate atypia on biopsy having a subsequent diagnosis of prostate cancer
  • Patterns of failure of patients treated with brachytherapy for localized disease
  • Quality of life following differing types of radiotherapy
  • Second-line antiandrogen therapy following initial failure of a first-line antiandrogen in advanced prostate cancer
  • Mood and cognitive changes in men receiving intermittent androgen deprivation therapy … MORE …

Abiraterone acetate for hormone-resistant prostate cancer

A paper published today in the Journal of Clinical Oncology suggests that a new agent has been identified for the treatment of end-stage prostate cancer. The paper is being quoted in the media and is likely to reinvigorate discussion about the merits and risks of agents targeting hormone synthetic pathways. Continue reading